Article Text

Download PDFPDF
Genomics and proteomics of retinopathy of prematurity: DNA-based prevention and treatment
  1. W V Good1,
  2. R L Gendron2
  1. 1
    Smith Kettlewell Eye Research Institute, San Francisco, USA
  2. 2
    Memorial University Newfoundland, Canada
  1. W Good, 2318 Fillmore St., San Francisco, CA 94115, USA; good{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Genetic factors play a role in causing retinopathy of prematurity: genetic evaluation could eventually lead to earlier identification of infants in need of screening and treatment

With the advent of new treatments and improved precision in the timing of treatment, retinopathy of prematurity (ROP) is slowly morphing into a chronic illness. To be sure, blindness in infancy from ROP remains a possible outcome, even with the best surgical management. Nevertheless, problems of reduced visual acuity, high myopia, nystagmus, strabismus, late retinal detachments, and glaucoma, occur in children who had severe ROP. These problems last a lifetime, even though they do not cause blindness in infancy.

What causes these chronic problems, and what causes the disease in the first place? We know a lot about some of the risk factors for ROP, such as low birth weight and gestational age. Is it simply peradventure that two similar infants, side by side in the same nursery, with the same general hospital course, could have highly discrepant outcomes? Why does one child with advanced ROP develop myopia, and another not? What are the factors …

View Full Text


  • Competing interests: None declared.

  • Dr Good is supported by a grant from The National Institutes of Health, National Eye Institute, EY015228.

Linked Articles